BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
- PMID: 28370407
- DOI: 10.1002/jbmr.3143
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
Abstract
This 21-week, open-label, phase 2a trial aimed to evaluate the pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing, anti-sclerostin antibody, in adults with moderate osteogenesis imperfecta (OI). Patients received BPS804 (three escalating doses each separated by 2 weeks [5, 10, and 20 mg/kg]) or no treatment (reference group). The primary efficacy endpoints were mean changes from baseline to day 43 in: procollagen type 1 N-terminal propeptide (P1NP), procollagen type 1 C-terminal propeptide (P1CP), bone-specific alkaline phosphatase (BSAP), osteocalcin (OC), and type 1 collagen cross-linked C-telopeptide (CTX-1). Mean change from baseline to day 141 in lumbar spine areal bone mineral density (aBMD) was also assessed. BPS804 safety and tolerability were assessed every 2 weeks. Overall, 14 adults were enrolled (BPS804 group: n = 9, mean age 30.7 years, mean aBMD Z-score -2.6; reference group, n = 5, mean age 27.4 years, mean aBMD Z-score -2.2). In the BPS804 group, P1NP, P1CP, BSAP, and OC were increased by 84% (p < 0.001), 53% (p = 0.003), 59% (p < 0.001), and 44% (p = 0.012), respectively, versus baseline (reference: P1NP, +6% [p = 0.651]; P1CP, +5% [p = 0.600]; BSAP, -13% [p = 0.582]; OC, -19% [p = 0.436]). BPS804 treatment downregulated CTX-1 by 44% from baseline (reference: -7%; significance was not tested for this biomarker), and increased aBMD by 4% (p = 0.038; reference group: +1%; p = 0.138). BPS804 was generally well tolerated. There were 32 adverse events reported in nine patients; none was suspected to be treatment-related. There were no treatment-related fractures. BPS804 stimulates bone formation, reduces bone resorption, and increases lumbar spine aBMD in adults with moderate OI. This paves the way for a longer-term, phase 3 trial into the efficacy, safety, and tolerability of BPS804 in patients with OI. © 2017 American Society for Bone and Mineral Research.
Keywords: ANTI-SCLEROSTIN ANTIBODY; CLINICAL TRIALS; DXA; OSTEOGENESIS IMPERFECTA; WNT.
© 2017 American Society for Bone and Mineral Research.
Similar articles
-
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.J Clin Invest. 2017 Jun 1;127(6):2148-2158. doi: 10.1172/JCI83731. Epub 2017 Apr 24. J Clin Invest. 2017. PMID: 28436937 Free PMC article. Clinical Trial.
-
Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.J Clin Endocrinol Metab. 2014 Feb;99(2):E311-9. doi: 10.1210/jc.2013-2244. Epub 2013 Nov 7. J Clin Endocrinol Metab. 2014. PMID: 24203063
-
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.J Clin Invest. 2014 Feb;124(2):491-8. doi: 10.1172/JCI71101. Epub 2014 Jan 27. J Clin Invest. 2014. PMID: 24463451 Free PMC article. Clinical Trial.
-
Antisclerostin Effect on Osseointegration and Bone Remodeling.J Clin Med. 2023 Feb 6;12(4):1294. doi: 10.3390/jcm12041294. J Clin Med. 2023. PMID: 36835830 Free PMC article. Review.
-
Finite element analysis of bone strength in osteogenesis imperfecta.Bone. 2020 Apr;133:115250. doi: 10.1016/j.bone.2020.115250. Epub 2020 Jan 22. Bone. 2020. PMID: 31981754 Free PMC article. Review.
Cited by
-
Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta.Calcif Tissue Int. 2024 Sep 4. doi: 10.1007/s00223-024-01263-8. Online ahead of print. Calcif Tissue Int. 2024. PMID: 39231826 Review.
-
Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model.Bone Rep. 2024 Jul 25;22:101795. doi: 10.1016/j.bonr.2024.101795. eCollection 2024 Sep. Bone Rep. 2024. PMID: 39185375 Free PMC article.
-
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.J Bone Miner Res. 2024 Sep 2;39(9):1215-1228. doi: 10.1093/jbmr/zjae112. J Bone Miner Res. 2024. PMID: 39012717 Free PMC article. Clinical Trial.
-
Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.Bone. 2024 Sep;186:117167. doi: 10.1016/j.bone.2024.117167. Epub 2024 Jun 13. Bone. 2024. PMID: 38876270 Free PMC article.
-
Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease.Mol Med. 2024 May 21;30(1):66. doi: 10.1186/s10020-024-00838-3. Mol Med. 2024. PMID: 38773377 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

